The integration of artificial intelligence into embryology, the spread of microfluidic sperm-selection technologies and the recalibration of PGT-A protocols added new layers of innovation to three decades of IVF practice this past year.
Many methods we labelled "experimental" in 2025 became the clinical standard in 2026. In preparing this annual at GynoLife IVF, we prioritised two things: putting forward success rates backed by scientific data, and connecting our patients' real stories to the human side of these medical breakthroughs.
On page 06 we spoke with our Embryology Director about the impact of AI-assisted embryo selection on success rates. On page 10 we look at why microchip IVF technology is now the first choice in male-factor cases.
According to our 2026 data, the live-birth rate in IVF cycles for patients under 35 reached 58.4% — a marked jump from 46% five years ago. What is behind this leap? You will find a detailed analysis on page 14.
As you read this annual, we want to underline one point: no matter how far technology advances, IVF is always a team effort. It is a path walked together by the embryologist, the clinician, the nurse and the patient. 2026 let us map that path more precisely; 2027 will be the first year personalised protocols are applied at scale.
Enjoy the read.
AI is not new to IVF laboratories; but 2026 was the year clinical decision-support tools moved from the "experimental" to the "routine" stage. More than 1,200 centres worldwide, GynoLife IVF among them, now use AI scoring algorithms paired with time-lapse imaging systems.
Traditional embryologist assessment relies on morphology: blastomere symmetry, fragmentation percentage, blastocyst quality. In addition to these, AI evaluates developmental speed, cell-division timing (kinetic parameters) and microscopic structural changes second by second.
A multi-centre analysis published during 2026 (n=4,328) reported an implantation rate of 62.1% for embryos selected with AI scoring versus 48.3% with classic morphological selection — a relative increase of about 23%. This difference reaches significance especially in patients over 38.
But AI is no magic wand. The system's success depends on the quality of its training data and the interpretability of the algorithm. The real breakthrough of 2026 was the spread of the "explainable AI" approach: the embryologist can now see, step by step, why the AI scored an embryo highly.
Our GynoLife IVF Embryology Director explains AI's place in the lab and expectations for 2027.
IVFMag: What was the biggest change of 2026 for you?
Making AI scoring standard across all our transfers. Where we once used it for selected patients, this year we moved to a dual-screening (AI + embryologist) protocol in every case. Consistency in outcomes rose significantly.
Do you share the concern that AI will replace the embryologist?
No, quite the opposite. AI freed us from our "subjective" side. On a tired day, after back-to-back cases, an embryologist's judgement can shift slightly; AI zeroes out that variation. But clinical context — the patient's history, accompanying factors, the transfer decision — is still human work.
What do you think about microchip IVF?
It was our biggest surprise of 2026. In male-factor cases, a sperm-selection step before ICSI clearly improved our clinical outcomes. In 2027 we will standardise it for all severe male-factor cases.
Summary data for all IVF, ICSI and donor programmes carried out at GynoLife IVF in 2026.
* Data cover fresh and frozen transfers from 1 January 2026 to 31 December 2026. Live birth after 24 weeks is taken as the basis. Donor programme success is reported for oocyte-donor IVF.
Mitochondrial donation, personalised protocol algorithms and in vitro gametogenesis — the three big themes on our agenda for the new year.
Mitochondrial donation moves closer to clinical practice. After the first births in the United Kingdom in 2025, the Netherlands and Australia clarified their regulatory frameworks in 2026. In 2027 we expect controlled clinical use to begin in at least five European countries.
Personalised stimulation protocols. Dosing algorithms based on the combined analysis of AMH + AFC + genetic markers reduce OHSS risk while increasing oocyte yield. We forecast these protocols will be standard in 40% of centres by mid-2027.
In vitro gametogenesis (IVG) is on the horizon. In animal models, a functional embryo was produced from a somatic cell in 2026. Clinical use in humans is at least 5–7 years away — but basic research has accelerated.
Artificial womb technology (uterine prosthesis) offers hope in premature care. First human trials for supporting babies born before 22 weeks are expected to begin in 2027.
We will cover all these topics in detail in our 2027 issues. Stay with us.